

Daniel Brook

Partner
London

Biography

Daniel is a patent litigator in the UK. He acts for clients such as MSD, Lilly, Amgen and BMS. Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).

He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.

Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.

Representative experience

Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.

Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.

Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.



Phone

+44 20 7296 5484

Fax

+44 20 7296 2001

Email

daniel.brook@hoganlovells.com

Languages

English

Practices

Patents

IP Litigation, Arbitration, and
Alternative Dispute Resolution

Industries

Life Sciences and Health Care
Technology & Telecoms

Areas of focus

IP Rights in Transactions

Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.

Awards and rankings

- Hot 100, *The Lawyer*, 2018
- Intellectual Property: Patent Litigation (UK), *Chambers Global*, 2017-2018
- Impact Case of the Year, *Managing Intellectual Property Awards*, 2018
- Intellectual Property: Patent Litigation, *Chambers UK*, 2014 - 2018
- Pharmaceuticals and biotechnology, *Legal 500*, 2013 - 2018
- Intellectual Property, *Legal 500*, 2013 - 2018
- IAM Patent 1000, 2013 - 2018
- Patents, *IP Star*, 2017 - 2018
- Patents, *Who's Who Legal*, 2018

Latest thinking and events

- Published Works
 - Patent Litigation 2021 guide *Chambers and Partners*
- Press Releases
 - Eli Lilly secures major win in its long-running patent dispute with Fresenius Kabi over oncology drug Alimta
- Insights
 - UK Supreme Court hands down eagerly awaited FRAND issues ruling in Unwired Planet
- Insights
 - UK Court of Appeal rules no interim injunction in patent case
- Hogan Lovells Publications
 - View from the Horizon: Artificial Intelligence and

IP Licensing, Commercialization, and Technology Transfer

Medical Devices

Pharmaceuticals and Biotechnology

Cell, Tissue, and Gene Therapies

Education and admissions

Education

M.A. Natural Sciences - Chemistry, University of Cambridge, 1999

M.Sci, University of Cambridge, 1999

Memberships

AIPPI Council Member

CIPA

EPLAW

Accolades

"Daniel Brook is 'technically very competent' and 'gets the ins and outs of even the most complex piece of patent litigation'".

Legal 500, 2018

Cannabusiness in London

- ■ London: Life Sciences and Health Care Horizons
2019